

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**Form 8-K**

**Current Report**  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): January 29, 2017**

**OPIANT PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction of incorporation)

**000-55330**

(Commission File Number)

**46-4744124**

(IRS Employer Identification No.)

**401 Wilshire Blvd., 12th Floor**  
**Santa Monica, CA**

(Address of Principal Executive Offices)

**90401**

(Zip Code)

**(424) 252-4756**

Registrant's telephone number, including area code

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On January 31, 2017, Opiant Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the establishment of an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee of the Company’s Board of Directors (the “Board”) on January 29, 2017. All three committees are comprised solely of directors who meet the independence requirements under the NASDAQ Stock Market Listing Rules. The membership of these three standing committees of the Board is now as follows:

<b>Audit Committee</b>	<b>Compensation Committee</b>	<b>Nominating and Corporate Governance Committee</b>
Mr. Thomas T. Thomas (Chairperson)	Ms. Ann MacDougall (Chairperson)	Dr. Gabrielle Silver (Chairperson)
Ms. Ann MacDougall	Mr. Thomas T. Thomas	Ms. Ann MacDougall
Mr. Geoffrey Wolf		Mr. Geoffrey Wolf
		Mr. Thomas T. Thomas

A charter for each of these committees of the Board, along with the Company’s Code of Business Conduct and Ethics, which was also approved by the Board on January 29, 2017, can be found on the Company’s website at <http://www.opiant.com/>.

The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

**Exhibit 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.    Description

99.1            Opiant Pharmaceuticals, Inc. Press Release, dated January 31, 2017.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Opiant Pharmaceuticals, Inc.**

Date: January 31, 2017

By: /s/ Dr. Roger Crystal

Name: Dr. Roger Crystal

Title: President and Chief Executive Officer

---



**FOR IMMEDIATE RELEASE**

**Opiant Pharmaceuticals, Inc. Announces Establishment of Audit, Compensation and Nominating and Corporate Governance Committees**

*Company to pursue up-listing to a major stock exchange in 2017*

SANTA MONICA, California – January 31, 2017 – Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB: OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that the Company’s Board of Directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. Copies of the Committee charters, along with the Company’s Code of Business Conduct and Ethics, can be found on the Investor Relations section of the Company’s website.

“When we established our milestones and objectives for 2017, key among them was the strengthening of our corporate governance,” said Dr. Roger Crystal, Chief Executive Officer of Opiant. “As we pursue an up-listing to a major stock exchange that raises the profile of our Company, we are committed to corporate governance practices that promote Board and management accountability, supporting our mission of creating innovative new addiction therapies for patients while creating long-term value for our shareholders.”

The composition of the Committees is as follows:

**Audit Committee**

Mr. Thomas T. Thomas (Chairperson), Ms. Ann MacDougall, Mr. Geoffrey Wolf

**Compensation Committee**

Ms. Ann MacDougall (Chairperson), Mr. Thomas T. Thomas

**Nominating and Corporate Governance Committee**

Dr. Gabrielle Silver (Chairperson), Ms. Ann MacDougall, Mr. Geoffrey Wolf, Mr. Thomas T. Thomas

All three committees are comprised solely of directors who meet the independence requirements under the NASDAQ Stock Market Listing Rules.

---

## **About Opiant Pharmaceuticals, Inc.**

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. Over 45 million people in the U.S. have one of these disorders. The National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company's partner, Adapt Pharma Limited. For more information please visit: [www.opiant.com](http://www.opiant.com).

## **Forward-Looking Statements**

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

###

## **CONTACT INFORMATION:**

### **Corporate Contact:**

[Investor.relations@opiant.com](mailto:Investor.relations@opiant.com)

### **Media:**

Susan Forman  
DGI  
[sforman@dgi-comm.com](mailto:sforman@dgi-comm.com)  
212-825-3210

### **Investors:**

Glenn Garmont  
Senior Vice President  
Argot Partners  
[glenn@argotpartners.com](mailto:glenn@argotpartners.com)  
212-600-1902

---